StemoniX, acquired by AxoSim

StemoniX, acquired by AxoSim

Biotechnology Research

Maple Grove, Minnesota 2,941 followers

Pre-plated, human iPSC-derived microOrgans for toxicology and drug discovery research

About us

AxoSim, Inc. acquired the microBrain™-associated assets of Vyant Bio’s StemoniX subsidiary in October 2023. The microBrain™ technology provides a physiologically relevant human iPSC-derived screening platform for CNS drug discovery and toxicity testing. The organoid platform replicates important human CNS biology, containing cortical neurons and astrocytes that self-organize and form functional networks in 3D. The hallmark of the microBrain™ organoids is their remarkably consistent performance, making them ideal for high-throughput neurotoxicology, neuromodulation, and drug discovery investigations. For more information about microBrain™ contact sales@axosim.com

Website
https://axosim.com/acquisition/
Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Maple Grove, Minnesota
Type
Privately Held
Founded
2014
Specialties
Human iPS Cells, Stem Cells, Cardiomyocytes, Neurons, Astrocytes, iPS Cell Manufacturing, Drug Discovery, High Throughput Screening, in vitro Assay Development, Disease Modeling, and Hazard Identification

Locations

Employees at StemoniX, acquired by AxoSim

Updates

Similar pages

Funding